AI Terminal
Medios AG
Business and Financial Review • Dec 13, 2024
282_rns_2024-12-13_30becbc3-0add-46b6-a8c9-554518ecc9af.html
Business and Financial Review
Open in ViewerOpens in native device viewer
News Details
Ad-hoc | 12 December 2024 13:27
Medios AG: Specification of the full-year forecast
Medios AG / Key word(s): Annual Results
Medios AG: Specification of the full-year forecast
12-Dec-2024 / 13:27 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
Adhoc release
Disclosure of inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014
Specification of the full-year forecast
Berlin, December 12, 2024 – Medios AG (“Medios”) specifies its full-year forecast as follows: The Company expects revenues of c. €1.85 billion (previous year: €1.8 billion which corresponds to an increase of 2.8%) and EBITDA pre 1 of c. €80 million (previous year: €60.5 million which corresponds to an increase of 32.2%). The EBITDA pre 1 margin is therefore expected to be around 4.3% (previous year: 3.4 %).
Previously, revenues of €1.9 billion to €2.1 billion and EBITDA pre 1 of €82 million to €91 million were expected. Accordingly, an EBITDA pre 1 margin of around 4.3% was previously expected.
1 EBITDA is defined as consolidated earnings before interest, taxes, depreciation and amortization. EBITDA pre is adjusted for special charges for stock options and expenses for M&A activities and expenses for ERP-System implementation as well as for one-time performance-based payments for the acquisition of compounding volumes.
Disclosing person: Matthias Gärtner, CEO
End of Inside Information
Contact
Medios AG, Heidestraße 9, 10557 Berlin
Telefon: +49 30 232 5668 00; Fax: +49 30 232 5668 01
E-Mail: [email protected] ; www.medios.group
——————-
About Medios AG
Medios is a leading provider of Specialty Pharma in Europe. With locations in Germany, the Netherlands, Belgium and Spain, the company supports key partners in the supply chain with innovative solutions and intelligent services. Medios has focused on pioneering individualized medicine to make the most innovative therapies available to everyone together with pharmacies, specialist practices and pharmaceutical companies.
Medios AG is Germany’s first listed specialty pharmaceutical company. The shares are listed on the regulated market of the Frankfurt Stock Exchange (Prime Standard) and are included in the SDAX selection index.
www.medios.group
Contact
Claudia Nickolaus
Head of Investor & Public Relations, ESG Communications
Medios AG
Heidestraße 9 | 10557 Berlin
T +49 30 232 566 800
Disclaimer
This communication contains forward-looking statements that are subject to certain risks and uncertainties. Future results could differ materially from those currently anticipated as a result of various risk factors and uncertainties, including, but not limited to, changes in business, economic and competitive conditions, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings and the availability of financing. Medios AG assumes no responsibility to update any forward-looking statements contained in this release.
End of Inside Information
12-Dec-2024 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com
| Language: | English |
| Company: | Medios AG |
| Heidestraße 9 | |
| 10557 Berlin | |
| Germany | |
| Phone: | +49 30 232 566 – 800 |
| Fax: | +49 30 232 566 – 801 |
| E-mail: | [email protected] |
| Internet: | www.medios.ag |
| ISIN: | DE000A1MMCC8 |
| WKN: | A1MMCC |
| Indices: | SDAX |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange |
| EQS News ID: | 2050181 |
| End of Announcement | EQS News Service |